Target intelligence / Profile preview

Stimulator of interferon genes (STING) (STING)

Target
STING
Molecular classification
Transmembrane protein, Adaptor protein, Innate immune sensor, Dimerizing protein
01

Overview

Stimulator of interferon genes (STING) is a critical adaptor protein in the innate immune system, primarily localized to the endoplasmic reticulum membrane. It functions as a central sensor for cyclic dinucleotides, most notably cyclic GMP-AMP (cGAMP), which is produced by the enzyme cGAS upon the detection of double-stranded DNA in the cytosol. Once activated, STING undergoes a conformational change and translocates to the Golgi apparatus, where it recruits TANK-binding kinase 1 (TBK1) to phosphorylate interferon regulatory factor 3 (IRF3), leading to the robust production of Type I interferons and other pro-inflammatory cytokines. In oncology, STING is a major therapeutic target for agonists designed to enhance anti-tumor immunity by activating the cGAS-STING pathway within the tumor microenvironment. Conversely, dysregulation or gain-of-function mutations in STING are associated with severe autoinflammatory conditions, leading to research into STING mRNA-targeting antisense oligonucleotides and small-molecule inhibitors to suppress pathological immune activation.

Other names
Transmembrane protein 173TMEM173Endoplasmic reticulum interferon stimulatorERISMediator of IRF3 activationMITAMPYSNET23
02

Mechanism of action

STING agonists bind to the STING dimer to induce a closed conformation that triggers downstream signaling for immune activation, while STING inhibitors or mRNA-targeting agents (siRNA/ASO) aim to reduce STING expression or activity to treat autoinflammatory diseases.

03

Biological functions

Innate immune responseType I interferon signalingCytosolic DNA sensingAutophagy inductionPro-inflammatory cytokine productionApoptosis regulation
04

Disease associations

CancerSTING-associated vasculopathy with onset in infancy (SAVI)Systemic lupus erythematosusAicardi-Goutières syndromeInfectious diseaseNonalcoholic steatohepatitis (NASH)
05

Safety considerations

Cytokine release syndrome (CRS)Systemic inflammatory responseAutoimmunityHepatotoxicityInjection site reactionsT-cell apoptosis at high doses
06

Interacting drugs

ADU-S100 (MIW815)

7 more in the full profile.

07

Biomarkers

Interferon-beta (IFN-β) levelsCXCL10 (IP-10) expressionPhosphorylated IRF3 (p-IRF3)Phosphorylated TBK1 (p-TBK1)ISG15 expressionSTING pathway gene signature

Beyond the preview

Go deeper on Stimulator of interferon genes (STING) (STING).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Stimulator of interferon genes (STING) (STING).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call